Details for New Drug Application (NDA): 062591
✉ Email this page to a colleague
NDA 062591 describes KEFUROX, which is a drug marketed by Acs Dobfar and Lilly and is included in three NDAs. Additional details are available on the KEFUROX profile page.
The generic ingredient in KEFUROX is cefuroxime sodium. There is one drug master file entry for this compound. Three suppliers are listed for this compound. Additional details are available on the cefuroxime sodium profile page.
The generic ingredient in KEFUROX is cefuroxime sodium. There is one drug master file entry for this compound. Three suppliers are listed for this compound. Additional details are available on the cefuroxime sodium profile page.
Summary for 062591
| Tradename: | KEFUROX |
| Applicant: | Acs Dobfar |
| Ingredient: | cefuroxime sodium |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INTRAMUSCULAR, INTRAVENOUS | Strength | EQ 750MG BASE/VIAL | ||||
| Approval Date: | Jan 10, 1986 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | EQ 1.5GM BASE/VIAL | ||||
| Approval Date: | Jan 10, 1986 | TE: | RLD: | No | |||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | EQ 7.5GM BASE/VIAL | ||||
| Approval Date: | Dec 17, 1987 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
